Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll. Mark Daniels, an 83-year-old veteran, pilot and gym ...

Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

Cell isolation and activation are critical for cell therapy development and manufacturing. Ease of use, regulatory compliant and financial sustainability are among the most important considerations.

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

Cell therapy manufacturing has long been constrained by manual bottlenecks - steps that are labor-intensive, variable, and difficult to scale. Robotic automation is increasingly becoming key to ...

An exclusive development deal integrates affinity based cell isolation into an automated system that rapidly extracts T cells from blood or apheresis. The approach aims to boost manufacturing ...